VKTX

Viking Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 2/10
  • Value↑ 6/10
Viking Therapeutics sales and earnings growth
VKTX Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -215.84%
  • FCF Y/Y↓ -217.45%
Viking Therapeutics gross and profit margin trends
VKTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -29.84%
Viking Therapeutics net debt vs free cash flow
VKTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Viking Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗